TABLE 2

Pharmacokinetic characteristics and distribution of CLR in pulmonary ELF and BALCs after monotherapy with 7.5 mg/kg CLR and after coadministration of 10 mg/kg RIF in nine healthy foals

Mean ± S.D. values are given.

	AUC_0–12h	Maximal Plasma Concentration	Minimal Plasma Concentration	Time to Maximal Plasma Concentration	t_1/2	Concentration at 12 h
	AUC_0–12h	Maximal Plasma Concentration	Minimal Plasma Concentration	Time to Maximal Plasma Concentration	t_1/2	ELF	BALCs
	μg × h/ml	μg/ml	μg/ml	h	h	μg/ml
CLR
Without RIF	4.76 ± 3.50	0.61 ± 0.37	0.21 ± 0.23	2.44 ± 0.65	7.17 ± 1.92	9.95 ± 19.9^††	116 ± 137^††
With RIF	1.17 ± 0.93^*	0.18 ± 0.14^*	0.05 ± 0.06	2.35 ± 1.67	7.25 ± 2.11	3.34 ± 5.54^*^††	24.8 ± 29.0^*^††
14OH-CLR
Without RIF	1.09 ± 0.64	0.13 ± 0.06	0.06 ± 0.05	2.48 ± 0.48	7.28 ± 1.35	0.16 ± 0.23^†	1.90 ± 1.17^††
With RIF	0.99 ± 0.66	0.12 ± 0.07	0.05 ± 0.04	2.72 ± 2.62	6.60 ± 1.76	0.08 ± 0.10^*	1.15 ± 0.78^††

↵* p < 0.05, versus without RIF (Wilcoxon test).
↵† p < 0.05,
↵†† p < 0.01, versus plasma concentration at 12 h (Mann-Whitney test).